

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/086403-2025>

Award

RMH clonoSEQ® Assay

The Royal Marsden NHS Foundation Trust

UK6: Contract award notice - Procurement Act 2023 - [view information about notice types](#)

Notice identifier: 2025/S 000-086403

Procurement identifier (OCID): ocds-h6vhtk-05fb40 ([view related notices](#))

Published 30 December 2025, 11:11am

Scope

Description

The procurement of a next-generation sequencing (NGS)–based test assay designed for the detection and monitoring of minimal residual disease (MRD) in patients with certain haematologic malignancies, such as multiple myeloma, acute lymphoblastic leukaemia (ALL), and chronic lymphocytic leukaemia (CLL).

The required goods and services include:

- Provision of assay kits and reagents suitable for the intended patient population.
- Use of a software platform for analysis and reporting of results.
- Training and technical support for laboratory and clinical staff to ensure accurate sample processing, data interpretation, and integration into clinical workflows.
- Ongoing technical support, maintenance, and updates for both hardware (if applicable) and software components.
- Delivery of consumables and reagents on a schedule that aligns with clinical demand, ensuring continuity of patient testing.

- Compliance with all relevant regulatory standards (e.g., CE-IVD, UKCA marking) and data protection requirements for patient information.
 - Optional: Integration with existing laboratory information management systems (LIMS) and electronic health records (EHR), if required.
 - MRD sensitivity threshold of 10⁻⁵ or lower
 - Must work on DNA
 - Performance data must be supported by evidence generated in relevant disease specific Clinical Trials
 - Recognised technology included in clinical guidelines
 - Ability to track clonal evolution
-

Contract 1. RMH clonoSEQ® Assay

Supplier

- Adaptive Biotechnologies Corporation

Contract value

- £1,158,208.33 excluding VAT
- £1,389,850 including VAT

Above the relevant threshold

Award decision date

22 December 2025

Standstill period

- End: 12 January 2026
- 8 working days

Earliest date the contract will be signed

15 January 2026

Contract dates (estimated)

- 20 January 2026 to 19 January 2031
- 5 years

Main procurement category

Goods

CPV classifications

- 33696500 - Laboratory reagents

Contract locations

- UKI - London

Procedure

Procedure type

Direct award

Supplier

Adaptive Biotechnologies Corporation

- Public Procurement Organisation Number: PBYH-2894-GJWD

1165 Eastlake Ave E, Seattle, United States

Seattle

WA 98109

United States

Email: dgalezowski@adaptivebiotech.com

Website: <http://www.adaptivebiotech.com>

Small or medium-sized enterprise (SME): Yes

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 1. RMH clonoSEQ® Assay

Contracting authority

The Royal Marsden NHS Foundation Trust

- Public Procurement Organisation Number: PXLT-9823-WVCY

Fulham Road

London

SW3 6JJ

United Kingdom

Contact name: Gemma Fahey

Email: gemma.fahey@nhs.net

Website: <https://www.royalmarsden.nhs.uk>

Region: UKI33 - Kensington & Chelsea and Hammersmith & Fulham

Organisation type: Public authority - central government

Other organisation

These organisations are carrying out the procurement, or part of it, on behalf of the contracting authorities.

Central London Community Healthcare NHS Trust

Summary of their role in this procurement: CLCH host a collaborative, outsourced procurement service - North West London Procurement Services.

- Public Procurement Organisation Number: PJXH-4297-MQQW

Ground Floor, 15 Marylebone Road

London

NW1 5JD

United Kingdom

Contact name: Gemma Fahey

Email: gemma.fahey@nhs.net

Website: <https://www.clch.nhs.uk>

Region: UKI32 - Westminster

Contact organisation

Contact The Royal Marsden NHS Foundation Trust for any enquiries.